Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07134712) titled 'Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II' on Aug. 14.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).
Primary Sponsor: HONYA Medical Co Ltd
Condition:
Acute Myocardial Infarction (AMI)
Intervention:
Biological: Cord Blood Nucleated cells
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 1, 2025
Target Sample Size: 100
Countries of Recruitment:
Taiwan
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07...